Table 1. Demographic and Clinical Characteristics of Study Participants.
| Characteristics | CHR participants (n=56) | Healthy controls (n=49) | Df | F/T/χ2 | p-Value |
|---|---|---|---|---|---|
| Gender M/F (number) | 41/15 (n=56) | 31/18 (n=49) | 1 | 1.2003 | 0.2733 |
| Age at MRI, years | 20.75 (SD 3.1) (n=56) | 21.17 (SD 3.79) (n=49) | 103 | 0.568 | 0.589 |
| Education, years | 13.02 (SD 2.35) (n=56) | 13.500 (SD 2.58) (n=42)a | 96 | −0.963 | 0.338 |
| Head motion (FD), mm | 0.144 (SD 0.07) (n=56) | 0.134 (SD 0.12) (n=49) | 103 | 0.890 | 0.616 |
| Minority/Caucasian (number) | 39/17 | 27/22 | 1 | 2.3667 | 0.124 |
| SIPS scores | |||||
| Total positive symptoms | 12.00 (SD 4.81) (n=56) | ||||
| Total negative symptoms | 14.69 (SD 7.35) (n=55)a | ||||
| CHR outcome | |||||
| Converted to psychosis | 11/56 (21.4%) (mean time to conversion: 19.18±11.90 months) | ||||
| Last GFS:Rb | 6.52 (n=44; SD=1.35) | ||||
| Last GFS:Sb | 5.84 (n=45; SD=2.8) | ||||
| Poor outcome | |||||
| (GFS:R=or <6) | 21/44 (47.7%) | ||||
| (GFS:S=or <6) | 21/45 (46%) | ||||
| Medication typec | |||||
| Atypical antispychotics | 10 (2 Quetiapine, 1 Olanzapine, 1 Ziprasidone, 2 Aripiprazole, 4 Risperidone) | ||||
| Typical antipsychotics | 0 | ||||
| Mood stabilizers | 1 (Lamotrigine) | ||||
| Antidepressants | 18 (Sertraline, Bupropion, Escitalopram, Venlafaxine, Fluoxetine, Citalopram, Paroxetine, Duloxetine) | ||||
| Stimulants | 5 (Adderall, Vyvanse, Concerta) | ||||
| Benzodiazepines | 6 (Clonazepam, Alprazolam, Lorazepam) | ||||
| Other | 1 (Gabapentin); 1 (Atomoxetine) | ||||
a
Indicates incomplete data.
b
The mean follow-up period (time to last follow up) was 21.84 months (n=45; SD=15.58).
c
Information about medication was unavailable for seven participants.